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Background: The mechanism of TGF-1-induced Akt kinase activation in diabetic nephropathy (DN) is not fully
elucidated.
Results: FOG2 down-regulation by TGF-1-induced miR-200b/c activates Akt, which leads to glomerular mesangial
hypertrophy.
Conclusion: FOG2 and miR-200b/c are novel modulators of TGF-1-induced Akt activation in glomerular mesangial cells.
Significance: These results reveal new mediators of TGF-1 actions related to the pathogenesis of DN.
Glomerular hypertrophy is a hallmark of diabetic nephropa-
thy. Akt kinase activated by transforming growth factor-1
(TGF-) plays an important role in glomerularmesangial hyper-
trophy. However, the mechanisms of Akt activation by TGF-
are not fully understood. Recently,miR-200 and its target FOG2
were reported to regulate the activity of phosphatidylinositol
3-kinase (the upstream activator of Akt) in insulin signaling.
Here, we show that TGF- activates Akt in glomerular mesan-
gial cells by inducing miR-200b and miR-200c, both of which
target FOG2, an inhibitor of phosphatidylinositol 3-kinase acti-
vation. FOG2 expression was reduced in the glomeruli of dia-
betic mice as well as TGF--treated mouse mesangial cells
(MMC). FOG2 knockdown by siRNAs in MMC activated Akt
and increased the protein content/cell ratio suggesting
hypertrophy. A significant increase of miR-200b/c levels was
detected in diabetic mouse glomeruli and TGF--treated
MMC. Transfection of MMC with miR-200b/c mimics signif-
icantly decreased the expression of FOG2. Conversely, miR-
200b/c inhibitors attenuated TGF--induced decrease in FOG2
expression. Furthermore, miR-200b/c mimics increased the
protein content/cell ratio, whereasmiR-200b/c inhibitors abro-
gated the TGF--induced increase in protein content/cell. In
addition, down-regulation of FOG2 by miR-200b/c could acti-
vate not only Akt but also ERK, which was also through PI3K
activation. These data suggest a new mechanism for TGF--
inducedAkt activation through FOG2down-regulation bymiR-
200b/c, which can lead to glomerular mesangial hypertrophy in
the progression of diabetic nephropathy.
Diabetic nephropathy (DN)2 is a major complication of dia-
betes. It is characterized by glomerular mesangial expansion
caused bymesangial cell hypertrophy, followed by extracellular
matrix protein accumulation and subsequent glomerulosclero-
sis (1–4). Cellular hypertrophy, a maladaptive increase in total
cell volume and protein content without a concomitant
increase in total cell number, is one of the early abnormalities
found inDN (5). In addition, chronic fibrotic changes have been
found to be preceded by hypertrophic growth (4, 6). Therefore,
understanding themechanisms associatedwith pathogenesis of
mesangial hypertrophy is important for the development of
approaches to treat DN.
The phosphatidylinositol 3-kinase (PI3K)-Akt pathway plays
a key role in cellular hypertrophy. The PI3K enzyme, a well
known upstream mediator of Akt kinase activation, is com-
posed of a catalytic subunit, p110, and a regulatory subunit,
p85. When activated, the catalytic subunit of PI3K recruits
Akt kinase to themembrane and activates it by phosphorylation
(7). Activated Akt phosphorylates several downstream proteins
that play central roles in hypertrophy, cell growth, cell survival,
and protein synthesis.
Transforming growth factor-1 (TGF-) is a major pro-
moter of diabetic renal manifestations. Enhanced expression of
TGF- in renal cells can lead to glomerular mesangial hyper-
trophy and fibrosis under diabetic conditions (2, 8–11). High
glucose conditions increase the transcription of TGF-1 (12,
13). Moreover, many of the effects of high glucose in renal cells
or the progression of DN were found to be attenuated by neu-
tralizing TGF-1 (10, 14). Therefore, TGF- is a critical medi-
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ator of the effects of high glucose in models of DN. Recent
studies have found that PI3K-Akt activation by TGF- plays a
key role in its downstream actions (15–18). Interestingly,
recent studies have shown that down-regulation of phospha-
tase and tensin homolog (PTEN) is a key mechanism by which
TGF- activates PI3K-Akt and that this occurs via microRNAs
(miRNAs) such as miR-216a/miR-217 that target PTEN (16,
19).
Growing evidence suggests thatmiRNAs play critical roles in
the progression of DN. miRNAs are a group of endogenously
produced, short noncoding RNAs that bind to the 3UTRs of
target mRNAs through base pairing and inhibit mRNA trans-
lation or promotemRNAdegradation (20, 21). SeveralmiRNAs
expressed in the kidney were found to be mis-regulated in the
renal cortex and glomeruli of animal models of diabetes as well
as in mouse and human mesangial cells treated with TGF- or
high glucose, and they could modulate the expression of extra-
cellularmatrix genes, suggesting a functional role in DN patho-
physiology (3, 19, 22–34).
Recently, a novel protein FOG2 was found to bind with the
p85, regulatory subunit of PI3K, thereby inhibiting PI3K acti-
vation (35). In addition, miR-200 was reported to decrease
FOG2 expression by targeting the 3UTR of the FOG2 mRNA,
thereby altering PI3K activity and regulating the insulin signal-
ing pathway andmetabolism (35).However, the role of FOG2 in
TGF- signaling and cellular hypertrophy has not been
examined.
In this study, we show that TGF- up-regulates miR-200b/c
in mouse mesangial cells (MMC) and subsequently down-reg-
ulates its target FOG2, which leads to PI3K-Akt activation and
glomerular mesangial hypertrophy. Furthermore, we obser-
ved that a FOG2 siRNA could directly increase Akt activity and
cellular hypertrophy, whereas inhibitors of miR-200b/c could
attenuate TGF--induced mesangial cellular hypertrophy.
These results reveal a novel new role for FOG2 regulated by
miR-200b/c in TGF--induced PI3K-Akt activation in the
pathogenesis of DN.
EXPERIMENTAL PROCEDURES
Animals—All animal studies were conducted according to
protocol approved by the Institutional Animal Care and Use
Committee at the Beckman Research Institute of City of Hope.
Type 2 diabetic db/db mice and genetic control nondiabetic
db/ mice (10–12 weeks old, eight per group), were obtained
fromThe Jackson Laboratory (Bar Harbor,ME). C57BL/6mice
(The Jackson Laboratory) were injected with 50mg/kg of strep-
tozotocin (STZ) intraperitoneally on 5 consecutive days. Mice
injected with diluent served as controls. Diabetes was con-
firmed by tail vein blood glucose levels (fasting glucose 300
mg/dl). Each group was composed of eight mice. All mice were
sacrificed at 16 weeks post-induction of diabetes. Glomeruli
were isolated from freshly harvested kidneys by a sieving tech-
nique. Renal capsules were removed, and the cortical tissue of
each kidneywas separated by dissection. The cortical tissuewas
then carefully strained through a stainless sieve with a pore size
of 150 m by applying gentle pressure. Enriched glomerular
tissue below the sieve was collected and transferred to another
sieve with a pore size of 75 m. After several washes with cold
PBS, the glomerular tissue remaining on top of the sieve was
collected. The pooled glomeruli were centrifuged, and the pel-
let was collected for RNA extraction. Each glomeruli sample
was composed of tissue pooled from two mice.
Cell Culture Experiments—MMC were obtained and cul-
tured as described previously in RPMI 1640 medium supple-
mented with 10% FBS (22). Passages 5–7 were used for experi-
ments. Recombinant human TGF-1 was from R&D Systems
(Minneapolis, MN). LY-294002 was from Calbiochem, and
MK-2206 was purchased from Selleck Chemicals (Houston,
TX). LY-294002 andMK-2206 were dissolved in dimethyl sulf-
oxide (DMSO) and used at a final concentration of 20 and 1M,
respectively, as described previously (36, 37).
Immunohistochemistry—Formalin-fixed, paraffin-embed-
ded sections of mouse kidneys were mounted onto positively
charged slides, deparaffinized, washedwithwater, blockedwith
Dako protein block (Dako, Carpinteria, CA), and incubated
with FOG2 antibody (1:25) for 30min. Slides were washed with
Dako wash, treated with hydrogen peroxide for 5 min, washed
with PBS, incubated with anti-rabbit secondary antibody con-
jugatedwith a peroxidase polymer (Dako,Carpinteria, CA), and
washed and incubated with 3,3-diaminobenzidine for 8 min.
Slides were counterstained with hematoxylin and mounted.
Images were taken at 40 magnification using an Olympus
BX51 microscope with In Studio (Pixera Corp., Santa Clara,
CA) software to collect images. ImagePro software (Media
Cybernetics Inc., Rockville, MD) was used to quantify staining.
Real Time Quantitative PCR—RNA was extracted using
miRNeasy columns (Qiagen, Inc. Valencia, CA). miRNA
expression analysis was performed with the qScript miRNA
cDNA synthesis kit (Quanta Biosciences, Gaithersburg, MD)
and PerfeCTa SYBR Green Supermix (Quanta Biosciences).
GeneAmp RNA PCR kit (Applied Biosystems, Carlsbad, CA)
and POWER SYBR Green mix (Applied Biosystems) were
used for mRNA quantification. Extracted mature miRNAs
were first polyadenylated with poly(A) polymerase followed
by reverse transcription into cDNA using oligo(dT) primer
with universal tag. miRNAs were amplified using specific
mature miRNA sequences as forward primers and the uni-
versal primer provided in the kit as reverse primer. Real time
quantitative PCRs were performed on the 7500 real time
PCR system (Applied Biosystems, Foster City, CA). PCR
primer sequences were as follows: FOG2, 5-GAGCTGCG-
AAGACGTGGAGT-3 and 5-CCAGGCTGTCCTGGTT-
TGTC-3; and TGF-1, 5-CAACGCCATCTATGAGA-3
and 5-AAGCCCTGTATTCCGTCTCC-3.
Western Blot Analysis—Immunoblotting was performed as
described previously (22). Cells were lysed in Laemmli’s sample
buffer. Lysates were fractionated on 10% SDS-polyacrylamide
gels (Bio-Rad) and transferred to nitrocellulose membrane.
Membranes were immunoblotted with appropriate antibodies.
Antibody against FOG2 was from Santa Cruz Biotechnology
(1:500). Antibodies against phospho-Akt, Akt, and-actinwere
from Cell Signaling (Beverly, MA). Blots were scanned using
GS-800 densitometer and quantified with Quantity One soft-
ware (Bio-Rad).
miRNA Oligonucleotides—Oligonucleotides representing
themiRmimics, negative control formimics (NC-M), themiR-
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200b/c inhibitors, and the negative control for the inhibitors
(NC-I) were all obtained from Thermo Fischer Scientific Inc.
(Waltham, MA).
MMCTransfection—Cells (1 106/transfection) were trans-
fected with siRNA ormiRNA oligonucleotides using an Amaxa
Nucleofector (Lonza, Basel, Switzerland) according to theman-
ufacturer’s protocols as described previously (19). MMC were
trypsinized and resuspended in Basic Nucleofection Solution at
1  107/ml. Subsequently, 100 l of cell suspension (1  106
cells) wasmixedwithmiRNAmimic, hairpin inhibitor oligonu-
cleotides, or ON-TARGET plus siRNA or negative controls
(Thermo Fischer Scientific Inc., Waltham, MA) as indicated.
Transfected cells were harvested for RNA and protein isolation
at indicated times.
Measurement of Cellular Hypertrophy—Hypertrophy was
assessed by measurement of cellular protein/cell counts as
described previously (19). MMC were trypsinized and counted
using a Coulter Counter with 100-m aperture (Beckman
Coulter, Brea, CA). Cells were lysed, and total protein content
was measured using protein assays from Bio-Rad.
Statistical Analysis—Statistical analysis was performed using
PRISM software (Graph-Pad, San Diego, CA) for data analysis
with Student t tests or analysis of variance. p  0.05 was con-
sidered statistically significant. All data were expressed as
means S.E.
RESULTS
FOG2 Expression Is Down-regulated in Glomeruli of Diabetic
Mice—To evaluate whether glomerular FOG2 is related to the
progression of DN, we first examined the expression of FOG2
in glomeruli of type 2 and type 1 diabetic mice. The immuno-
histochemical staining of FOG2 was significantly decreased in
glomeruli from type 2 diabetic db/dbmice compared with non-
diabetic control mice (db/) (Fig. 1,A–C). FOG2mRNA levels
were also significantly lower in the renal glomeruli of the dia-
betic db/dbmice when compared with control db/mice (Fig.
1D). Conversely,TGF-1 gene expression levels were increased
in the glomeruli from db/dbmice (Fig. 1E). A similar decrease
in FOG2 staining was observed in glomeruli from streptozoto-
cin-induced type 1 diabetic mice (STZ) compared with nondi-
abetic control mice (CON) (Fig. 1, F–H). FOG2 mRNA levels
were lower in STZ glomeruli (Fig. 1I), whereas TGF-1 expres-
sion levels were significantly higher (Fig. 1J).
FOG2 Expression Is Down-regulated in MMC Treated with
High Glucose and with TGF-—To further clarify whether the
glomerular expression of FOG2 is regulated by diabetic condi-
tions in vitro, MMC were cultured with either normal glucose
(NG, 5.5mM) or high glucose (HG, 25mM) for 72 h. The expres-
sion of FOG2mRNA and protein was significantly down-regu-
lated by HG relative to NG treatment (Fig. 2, A–C). The down-
regulation of FOG2 in HG-treated MMC was associated with
an increase in Akt phosphorylation (Fig. 2, B and D). These
changes were accompanied by a significant increase of TGF-1
expression in HG-treated MMC (Fig. 2E). Because TGF- is
increased in renal cells under diabetic conditions, is up-regu-
lated by HG, and plays a key role in the pathogenesis of DN, we
next examined the effects of TGF-. TGF- treatment inMMC
resulted in a significant decrease in FOG2 mRNA (from 6 to
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FIGURE 1. Decreased levels of FOG2 in glomeruli from mouse models of
type 2 (db/db) and type 1 diabetes (streptozotocin-induced). A and B,
representative immunohistochemistry staining of FOG2 in glomeruli from
genetic control db/ mouse (scale bar, 20 m) (A) and from diabetic db/db
mouse (B). C, percentage of FOG2-positive area. Significant decrease of FOG2
staining is observed in glomeruli from db/dbmice comparedwith those from
genetic control db/mice. To quantify the expression of FOG2, the positive
stained areas/glomerular areas (%) were measured using ImageJ (National
Institutes of Health). For each animal, 10 glomeruli were evaluated. Mean
S.E. D, FOG2 mRNA expression in glomeruli. Significant decrease of FOG2
mRNA in glomeruli from db/dbmice compared with those from genetic con-
trol db/mice. E, TGF-1mRNA expression in glomeruli. Significant increase
in TGF-1 mRNA in glomeruli from db/db mice compared with those from
genetic control db/ mice. Glomeruli were isolated by a sieving technique
from eightmice in each group. Results were normalizedwith internal control
18 S. Mean S.E. F and G, representative immunohistochemistry staining of
FOG2 in glomeruli from control (CON) mouse (scale bar, 20 m) (F) and from
STZ-induced diabeticmouse (G).H, percentage of FOG2-positive area. Signif-
icant decrease of FOG2 staining is observed in glomeruli from STZ compared
with those from CON mice. For each animal, 10 glomeruli were evaluated.
Mean  S.E. I, FOG2 mRNA expression in glomeruli. Significant decrease of
FOG2 mRNA in glomeruli from STZ mice compared with those from CON
mice. J, TGF-1mRNA expression in glomeruli. Significant increase in TGF-1
mRNA in glomeruli from STZ mice compared with those from CON mice.
Glomeruli were isolated by a sieving technique from eight mice in each
group. Results were normalizedwith internal control 18 S.Mean S.E. ** and
* indicate p 0.01 and p 0.05, respectively.
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24 h; Fig. 3A) and protein levels (from 1 to 24 h; Fig. 3, B andC).
Furthermore, in parallel, there was a significant increase in Akt
phosphorylation in the TGF--treated MMC (Fig. 3, B and D).
Together, these results suggest that FOG2 expression is
decreased in mesangial cells under diabetic conditions in vivo
and in vitro, and this is associated with an increase in Akt phos-
phorylation. In addition, the findings imply that these changes
are associated with TGF- expression, suggesting a link
between FOG2 inhibition and Akt phosphorylation in glomer-
ular mesangial cells under diabetic conditions.
Knockdown of FOG2 Activates Akt inMouseMesangial Cells—
Next, we tested the functional relevance of FOG2 down-regu-
lation in MMC. Recently, FOG2 and its fly analog U-shaped
(USH)were found to suppress PI3K activity and thereby repress
insulin receptor signaling in human cell lines and Drosophila
melanogaster to control growth (35). Therefore, we investi-
gated whether FOG2 also affects the phosphorylation of Akt, a
downstream target of PI3K, in MMC. FOG2 gene silencing by
transfection with specific siRNAs (siFOG2) resulted in a signif-
icant decrease in FOG2 mRNA (Fig. 4A) as well as FOG2 pro-
tein levels (Fig. 4, B and C) relative to nontargeting control
siRNA (siNTC). Furthermore, siFOG2 transfection also signif-
icantly increased the phosphorylation of Akt relative to siNTC
transfection in MMC (Fig. 4, B and D), suggesting that the
down-regulated FOG2 in TGF--treated cells may have a func-
tional relationship with Akt activation in MMC.
Previous studies have shown that glomerular mesangial
hypertrophy, a major feature of DN, is a downstream conse-
quence of Akt activation (16, 19). We next tested whether the
increase in Akt phosphorylation ensued by FOG2 knockdown
also results in increased cellular hypertrophy in MMC. TGF-
significantly increased cellular protein content, verifying that
MMChypertrophy is induced by TGF- (Fig. 4E). Transfection
of siFOG2 similarly induced hypertrophy in serum-depleted
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FIGURE2.Highglucosedecreases theexpressionofFOG2 inMMC.A, FOG2
mRNA levels in MMC treated with NG (5.5 mM) or HG (25 mM). Significant
decreasewas detected at 72 h after HG treatment comparedwith NG. Results
were normalized with internal control 18 S. Mean S.E. (n 4). B, immuno-
blotting analysis of MMC after treatment with HG (25 mM for 72 h). C, HG
treatment significantly decreasedprotein levels of FOG2 (normalized to-ac-
tin).Mean S.E. (n4).D,phosphorylationofAkt (p-Akt) (normalized to total
Akt) significantly increasedwith HG treatment. Mean S.E. (n 4). E, TGF-1
mRNA levels inMMCwithHG treatment. Significant increase in TGF-1mRNA
inMMC treatedwith HG for 72 h comparedwith NG. Results were normalized
with internal control 18 S. Mean S.E. (n 4). ** and * indicate p 0.01 and
p 0.05, respectively versus NG.
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FIGURE3.TGF-decreases theexpressionofFOG2 inMMC.A, FOG2mRNA levels inMMCtreatedwithTGF-. Significantdecreasewasdetectedat 6 and24h
after TGF- treatment. Results were normalized with internal control 18 S. Mean S.E. (n 4). B–D, immunoblotting analysis of MMC after treatment with
TGF- (10 ng/ml for 1 h to 24 h). C, TGF- treatment significantly decreased protein levels of FOG2 at 1–24 h (normalized to -actin). Mean  S.E. (n  4).
D, phosphorylation of Akt (p-Akt) (normalized to total Akt) significantly increasedwith TGF- treatment. Mean S.E. (n 4). ** and * indicate p 0.01 and p
0.05, respectively versus S.D.
FOG2 andmiR-200b/c inMesangial Cell Hypertrophy in Diabetes
22472 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 31•AUGUST 2, 2013
glomerular mesangial cells (Fig. 4E), confirming that the down-
regulation of FOG2 can enhance cellular hypertrophy inMMC.
Together these results suggest that the down-regulation of
FOG2 by TGF- under diabetic conditions can augment Akt
kinase activation and subsequently result in glomerularmesan-
gial cell hypertrophy.
miR-200b/c Are Up-regulated inMMCTreated with HG and
TGF-, as Well as in Glomeruli of Diabetic Mice—miR-200b
and miR-200c were recently shown to target FOG2 in human
cell lines. Similarly, in D. melanogaster the corresponding fly
analog miR-8 could target U-shaped (USH) (35). In addition,
the 3UTR of FOG2 is highly conserved in humans and mice.
Therefore, we examined whether FOG2 could also be down-
regulated by miR-200b/c under diabetic conditions in MMC.
First, miR-200b/c expression levels were evaluated in HG-
treated MMC. miR-200b and miR-200c levels were signifi-
cantly increased in MMC after 72 h of HG treatment (Fig. 5A).
A similar increase inmiR-200b andmiR-200c was also found in
MMC treated with TGF- (24 h) (Fig. 5B). miR-200b/c levels
were further evaluated in glomeruli of db/db and STZ mice.
miR-200b and miR-200c levels were significantly increased in
glomeruli of db/dbmice (Fig. 5C) as well as STZ mice (Fig. 5D)
compared with corresponding control mice as reported previ-
ously (27, 28), verifying that miR-200b and miR-200c are up-
regulated in glomerular mesangial cells and renal glomeruli
under diabetic conditions.
FOG2 Is Down-regulated by miR-200b/c in MMC—Next, we
examined whether miR-200b/c could down-regulate FOG2 in
MMC. Transfection of MMC with oligonucleotide mimics of
miR-200b (200b-M) or miR-200c (200c-M) significantly
increased the levels of miR-200b and miR-200c, respectively,
verifying the effectiveness of the mimics (Fig. 6A). Further-
more, results showed that 200b-M and 200c-M transfection
significantly down-regulated both FOG2 mRNA (Fig. 6B) and
protein levels (Fig. 6,C andD) relative to those transfected with
negative control mimic (NC-M) oligonucleotides, suggesting
that FOG2 abundance can be decreased by the up-regulated
miR-200b/c in glomerular mesangial cells under diabetic
conditions.
Akt Is Activated by miR-200b/c in MMC—Because our
results showed that FOG2 can suppress the phosphorylation of
Akt, we next evaluated whether the 200b-M and 200c-M
induced down-regulation of FOG2 could also up-regulate Akt
phosphorylation in MMC. Results showed that Akt phosphory-
lation was indeed significantly increased in MMC transfected
with 200b-M and 200c-M compared with NC-M-transfected
cells (Fig. 6, C and E), which occurred in parallel, to the down-
regulation of FOG2 (Fig. 6, C and D).
miR-200b/c Inhibitors CanAttenuate the Down-regulation of
FOG2 by TGF- inMMC—To verify that FOG2 is regulated by
miR-200b/c in glomerular mesangial cells under diabetic con-
ditions, we further investigated whether TGF--induced
down-regulation of FOG2 can be reversed by oligonucleotide
inhibitors of miR-200b/c. Transfection with hairpin inhibitor
oligonucleotides of miR-200b (200b-I) and miR-200c (200c-I)
resulted in a significant decrease in miR-200b and miR-200c
levels, respectively (Fig. 7A). Treatment of MMC with
TGF- and NC-I significantly down-regulated both FOG2
mRNA (Fig. 7B) and protein levels (Fig. 7, C and D) relative
to MMC with NC-I alone. However, the FOG2 mRNA (Fig.
7B) and protein levels (Fig. 7, C and D) decreased by TGF-
treatment were both significantly restored in cells trans-
fected with a mixture of 200b-I and 200c-I. These results
further verify that TGF--induced miR-200b/c under dia-
betic conditions can down-regulate the expression of FOG2
in glomerular mesangial cells.
miR-200b/c Inhibitors Attenuate Akt Activation in TGF--
treated MMC—Because the inhibition of miR-200b/c attenu-
ated the down-regulation of FOG2 in TGF--treated MMC,
and FOG2 down-regulates Akt phosphorylation, we further
tested whether inhibition of miR-200b/c could also reverse the
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FIGURE 4. Down-regulation of FOG2 induces Akt phosphorylation in
MMC. A, transfection with siFOG2 significantly decreased mRNA levels of
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TGF--induced increase in Akt phosphorylation in MMC.
Treatment ofMMCwith TGF- significantly up-regulated Akt
phosphorylation relative to untreatedMMCas expected (Fig. 7,
C and E). However, in 200b-I- and 200c-I-transfected MMC,
TGF--induced Akt phosphorylation was significantly attenu-
ated compared with that seen in NC-I-transfected MMC (Fig.
7, C and E).
FOG2 Down-regulation Activates ERK as Well as Akt in a
PI3K-dependent Manner in MMC—MMC transfected with
siFOG2 and 200b-M were treated with a PI3K inhibitor,
LY-294002, and Akt-specific inhibitor, MK-2206 (36, 38), to
confirm that increased Akt phosphorylation is via PI3K signal-
ing mediated by miR-200b/c-induced FOG2 down-regulation.
FOG2 protein levels were significantly decreased in siFOG2-
transfected MMC compared with siNTC-transfected MMC
(Fig. 8, A and B). Akt was activated in siFOG2-transfected
MMC. This increase in Akt phosphorylation was significantly
reduced inMMC treated with LY-294002 andMK-2206 (Fig. 8,
A and C). The activation of ERK was also evaluated in MMC
transfected with siFOG2 and 200b-M treated with LY-294002
and MK-2206 to investigate whether Akt was the only down-
stream pathway affected by FOG2 and miR-200b/c. ERK was
significantly activated in siFOG2-transfected MMC as evi-
denced by increased phospho-ERK levels. This activation was
significantly attenuated by LY-294002 treatment. However,
ERK activation was not significantly affected by MK-2206 (Fig.
8, A and D).
Similarly, in 200b-M transfectedMMC, FOG2 protein levels
were significantly decreased (Fig. 9, A and B). This was accom-
panied by an increase in Akt phosphorylation. Activated Akt in
200b-M-transfected MMC was attenuated in LY-294002- and
MK-2206-treated MMC (Fig. 9, A and C), showing that Akt
activation associated with FOG2 down-regulation induced by
miR-200b/c is PI3K-dependent. In addition, ERK phosphory-
lationwas significantly increased in 200b-M-transfectedMMC,
and this was significantly attenuated by LY-294002 treatment.
However, increased ERK phosphorylation induced by 200b-M
was not blocked byMK-2206, suggesting that ERK is not down-
stream of Akt in MMC (Fig. 9, A and D). These results suggest
that, in addition to Akt, ERK is also activated through miR-
200b/c-induced FOG2 down-regulation. Moreover, the results
also suggest that FOG2-regulated activation of both Akt and
ERK is through a common upstream effector, PI3K.
miR-200b/c Enhance Hypertrophy in MMC—Because miR-
200b/c could down-regulate FOG2 and subsequently enhance
Akt phosphorylation, we further examined whether miR-
200b/c can also directly increase glomerular mesangial cell
hypertrophy, a downstream consequence of Akt or ERK phos-
phorylation. Transfection of MMC with 200b-M or 200c-M
significantly increased cellular protein content compared with
control NC-M-transfectedMMC (Fig. 10A). In addition, trans-
fection with a mixture of 200b-I and 200c-I significantly atten-
uated the TGF--induced increase in cellular protein content
relative to that seen in NC-I-transfected MMC (Fig. 10B).
These results suggest that, in response to TGF- or diabetic
conditions, up-regulatedmiR-200b/c, which targets FOG2, can
lead to a down-regulation of FOG2 and subsequent increase in
Akt (and ERK) phosphorylation to promote hypertrophy in
MMC (Fig. 11).
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DISCUSSION
In this study, we showed for the first time that diabetic con-
ditions can down-regulate FOG2 and that the down-regulation
of FOG2 plays a role in TGF--induced Akt activation in MC.
In addition, FOG2 down-regulation by miR-200b and miR-
200c was demonstrated to induce hypertrophy in MMC, thus
identifying FOG2 as a new regulator in the pathogenesis of DN.
Moreover, we have shown that, in addition to Akt, ERK, which
is also one of the key players implicated in DN, could also be
activated by the down-regulation of FOG2.
Our current results demonstrate an additional novel path-
way by which Akt is activated by TGF-. Accumulating evi-
dence shows that TGF- plays a key role in the pathogenesis of
DN, which has been attributed to the activation of its down-
stream targets (1, 2, 10, 11). The Smad signaling pathway has
been the best characterized effector of TGF- receptor activa-
tion and signaling in DN progression (39, 40). However, the
PI3K-Akt pathway has also been implicated in mediating the
cellular effects of TGF- in DN (15, 17, 18). Reports show that
the PI3K-Akt signaling cascade triggered by TGF- induces
glomerular mesangial and renal tubular hypertrophy, impor-
tant pathologic phenotypic changes in the course of DN pro-
gression (16, 41). Because of its well known role as a signal
transducer of TGF- in DN, the mechanisms by which TGF-
activates Akt has elicited much interest. Down-regulation of
PTENbyTGF- has been implicated inAkt activation (16), and
recently, we showed that miR-216a- and miR-217-mediated
down-regulation of PTEN, which de-phosphorylates phos-
phatidylinositol 1,4,5-trisphosphate to inhibit Akt activation, is
a key mechanism of Akt activation by TGF- in MMC (19). In
addition to these previously suggested pathways, our current
results demonstrate that another mechanism involving miR-
200b/c targeting FOG2, which inhibits PI3K activity, can also
contribute to TGF--induced Akt activation in mesangial cells
under diabetic conditions. These results imply that TGF- acti-
vatesAkt through several indirectmechanismsmediated by key
miRNAs and signaling intermediates. One report showed that,
although TGF- receptor activation induces PI3K activity, the
TGF- receptor and the regulatory subunit of PI3K do not bind
directly (18) thereby suggesting several modes of Akt activation
mechanisms, including our proposed indirect models.
The role of FOG2 in disease pathophysiology has not been
clearly investigated although its physiologic functions have
been demonstrated only recently. Previous studies have been
mainly focused on the role of FOG2 in hematopoiesis and heart
development (42, 43). In addition, FOG2was found to be down-
regulated in lung and prostate cancers, suggesting that it may
possess tumor suppressor properties (44, 45). As indicated ear-
lier, a recent study suggested that FOG2 plays a key role in
insulin signaling in liver cells and adipocytes, although the
physiologic relevance is not fully clear (35). Insulin receptor
activation is known to transduce its signal through the PI3K-
Akt pathway. FOG2 was shown to act as a negative modulator
of the PI3K-Akt pathway by directly binding to p85, the reg-
ulatory subunit of PI3K. Additionally, by targeting FOG2, the
miR-200 family was implicated in the down-regulation of
FOG2 to facilitate insulin signaling (35). Although these new
players, miR-200 and FOG2, have broadened the understand-
ing of physiologic Akt activation mechanisms in insulin signal-
ing, the role of FOG2 in disease states is less understood. The
results of this study reveal a novel new protective role for FOG2
against pathologic PI3K-Akt activation and hypertrophy in the
glomerular mesangium in a disease state such as DN. In addi-
tion, they demonstrate that down-regulation of FOG2 can aug-
ment TGF--mediated signaling and Akt activation.
Interestingly, a recent transcriptome analysis of human renal
glomeruli and tubular tissue from patients with diabetic kidney
disease showed that FOG2 (also known as ZFPM2) transcript
expression was significantly decreased in renal glomeruli of
patients with DN compared with glomeruli from control
healthy kidneys. However, FOG2 expression levels did not dif-
fer in tubular tissue from DN patients compared with healthy
controls (46). This report supports the significance of FOG2
down-regulation in diabetic glomerulopathy and our observa-
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tion that FOG2 levels are lower in the glomeruli of both type 1
and type 2 diabetic mice. It also suggests that FOG2 might not
play a significant role in renal tubular pathophysiology under
diabetic conditions. Furthermore, the decreased FOG2 tran-
script expression in glomeruli from human subjects with DN
suggests that the proposed miR-200-FOG2-Akt pathway may
be significant not only in experimental animal models but also
in human diabetic kidney disease as well.
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It is possible that TGF- induced in mesangial cells under
diabetic conditions can up-regulate miR-200b/c via Smad3. A
recent report demonstrated that Smad3 directly binds to a
Smad-binding element located in the promoter region of miR-
200b, functioning as a transcriptional activator in gastric cancer
cells (47). In addition, our previous results have shown that
miR-192 induced by TGF- can target and down-regulate
Zeb1/2 (E-box repressors) and thereby enhance the expression
of miR-200b/c probably through E-boxes in their promoters
(27). Moreover, miR-200 family also targets Zeb1/2, further
enhancing the expression of miR-200 family itself through a
positive feedback loop under diabetic conditions (27). miR-
200b was reported to be up-regulated not only in mesangial
cells but also in endothelial cells and podocytes treated with
high glucose (28). In addition, increased levels of the miR-200
family members were also observed in human kidneys from
hypertensive nephrosclerosis, IgA nephropathy, and lupus
nephritis patients, suggesting a key role for miR-200 in renal
diseases and TGF- actions (48–50). We recently demon-
strated a pro-fibrotic role for miR-200b/c in enhancing the
expression of TGF-, collagen type I -2, and collagen type IV
-1, by targeting Zeb1/2, repressors that bind to the promoters
of these genes (27). In this study, we found thatmiR-200b/c can
down-regulate FOG2, an inhibitor of PI3K. Our observation
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that there is amore rapid decrease in FOG2 protein levels com-
pared with mRNA levels after TGF- treatment in MMC (Fig.
3, A and B) further supports the operation of this post-tran-
scriptional regulation. The current results suggest that, in addi-
tion to accelerating renal fibrosis, miR-200b/c play a role in
transducing TGF- signals by activating the PI3K-Akt path-
way, thereby promoting glomerular mesangial hypertrophy. It
is also noteworthy that a single miRNA (miR-200) family can
act onmultiple targets (Zeb1/2 and FOG2), which work in con-
junction to manifest the pathologic changes seen in the kidney
under diabetic conditions.
miR-200a has also been reported to be decreased in some
models of increased renal fibrosis and epithelial to mesenchy-
mal transition (32), which could be due to differences in the
models and experimental conditions used as well as cell type
specificity in the actions ofmiR-200 familymembers. However,
Kim et al. (51) showed that miR-200a and miR-141 are not
efficiently extracted because of lowGC content. Therefore, it is
possible that in some instances, the levels of low GC content
miRNAs like miR-200a may be underestimated even though
they are not decreased (and likely even increased). miR-200b
(not affected by extraction methods according to the same
paper) was shown to be increased in some reports (27, 28). In
this study, we also detected increased levels of miR-200b and
miR-200c under our experimental conditions.
It is possible that FOG2 is also regulated by other miRNAs
besides miR-200b/c. miRNAs such as miR-103 and miR-183
have potential binding sequences in the 3UTR of FOG2 (pre-
dicted by TargetScan). Several miRNAs that are highly
expressed in the kidney have been previously found to be up-
regulated in the glomeruli of diabetic animal models compared
with corresponding controls (3, 19, 22, 27–29, 34, 52, 53). In
addition, some of these miRNAs were also shown to be
increased inHG- or TGF--treatedmesangial cells (27–29, 34).
However, in these studies,miRNAs potentially targeting FOG2,
other than miR-200b/c, were not found to be differentially
expressed in the diabetic environment in the kidney or mesan-
gial cells, thus supporting the notion that miR-200b/c could be
the main miRNAs regulating FOG2 in renal glomeruli or MC
under diabetic conditions. Nevertheless, the involvement of
other miRNAs cannot be fully ruled out.
Akt has been shown to be activated in response to TGF-
signaling in several cell types (15, 19, 54). TGF- also enhances
Akt phosphorylation in multiple renal cells, including glomer-
ular mesangial cells, podocytes, and renal tubular cells (15, 19,
37, 55, 56). However, in hematopoietic cells, TGF- has been
shown to inhibit Akt phosphorylation by inducing the phos-
phatase SHIP, an inhibitor of Akt activation (57). In addition, in
adult hepatocytes, TGF- failed to activate Akt (58). Therefore,
although our results demonstrate that FOG2 can modulate
TGF--Akt signaling in glomerular mesangial cells, the role of
FOG2 in TGF- signal transduction may also be cell type- as
well as disease-specific.
Interestingly, ERK was also activated during miR-200b/c-in-
duced FOG2 down-regulation. ERK activation is known to be
involved in TGF--induced collagen expression as well as HG-
induced cellular hypertrophy in mesangial cells (59–61).
Blockage of ERK by specific ERK inhibitors has been shown to
attenuate high glucose-induced cellular hypertrophy and
fibronectin expression inmesangial cells and renal tubular cells
(62, 63), suggesting ERK as one of the signaling pathways in the
progression of DN alongwithAkt (64). However, themolecular
mechanisms by which TGF- activates ERK are not fully
understood. The present findings raise the possibility that
FOG2 down-regulation by miR-200b/c could be a common
pathway in PI3K-dependent activation of both Akt and ERK,
regulating both the early hypertrophic features as well as later
glomerular fibrotic characteristics ofDN.Therefore, the patho-
logic changes found in mesangial cells under diabetic condi-
tions might be due to the activation of both Akt and ERK
through a common effector, PI3K.
The up-regulation of FOG2 by miR-200b/c inhibitors in
TGF--treated cells was sufficient not only to attenuate Akt
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FIGURE 11. Schematic model of Akt and ERK activation and hypertrophy
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activation but also to abrogate TGF--induced hypertrophy.
Renal hypertrophy is recognized as an early pathologic finding
in the course of DN progression (5). In addition, hypertrophic
growth precedes fibrotic changes in the kidney under diabetic
conditions (6). Therefore, repressing renal hypertrophy by
inhibitingmiR-200b/c and restoring FOG2 in the early stages of
DN could be novel approaches to slow down disease progres-
sion. Further in vivo investigations are necessary to evaluate
this.
In summary, the current results demonstrate that post-tran-
scriptional regulation of FOG2, a target of miR-200b/c which
are induced by TGF- in MMC, plays a role in activating the
PI3K-Akt-ERK pathway under diabetic conditions (Fig. 11).
This new link could be an additional novelmechanismbywhich
TGF- induces cellular hypertrophy and fibrosis in DN,
thereby leading to renal disease progression.
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